Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment
Conclusion:
Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.
Source: Clinical and Applied Thrombosis/Hemostasis - Category: Hematology Authors: Dranitsaris, G., Shane, L., Burgers, L., Woodruff, S. Tags: Original Articles Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Health | Health Management | Hematology | Oral Cancer | Thrombosis | Vitamin K | Vitamins